The Nautilus system (Endostream Medical)—a self-conforming intrasaccular flow diverter intended for the treatment of intracranial aneurysms—heralds the “next evolution” in these types of neurovascular devices.
That is according to J Mocco (Mount Sinai, New York, USA), who spoke to NeuroNews at this year’s European Society of Minimally Invasive Neurological Therapy (ESMINT) congress (4–6 September, Marseille, France) to discuss how the technology works and provide an update on clinical usage of the device to date.
The Nautilus intrasaccular system is CE-marked and available for sale in Europe but, as of October 2023, is not approved by the US Food and Drug Administration (FDA) for sale or distribution in the USA, and is limited by US law to investigational use.
DISCLOSURES: The interviewee is a medical advisor and financial investor for Endostream Medical.
